Background: Mice infected with HSV-1 can develop lethal encephalitis or virus induced CNS demyelination. Multiple factors affect outcome including route of infection, virus and mouse strain. When infected with a sublethal dose of HSV-1 strain 2 via the oral mucosa, susceptible SJL/J, A/J, and PL/J mice develop demyelinating lesions throughout the brain. In contrast, lesions are restricted to the brainstem (BST) in moderately resistant BALB/ c mice and are absent in resistant BL/6 mice. The reasons for the strain differences are unknown. Methods: In this study, we combine histology, immunohistochemistry, and in-situ hybridization to investigate the relationship between virus and the development of lesions during the early stage (< 24 days PI) of demyelination in different strains of mice.
Background
HSV-1 is a common infection in developed countries where rates of seropositivity usually exceed 50% [1, 2] . In both humans and experimental animals, primary infection of the skin or mucosa results in the local replication of virus, infection of sensory nerve endings, and spread via retrograde axonal transport to the ganglia of the peripheral nervous system (PNS) where a productive infection of neurons ensues [1, 2] . Although infectious virus is eventually cleared, a latent infection is established in neurons of the PNS ganglia [3, 4] .
HSV-1infection of the CNS is more complex with virus transmitted across synapses during primary infection and the development of latent infection in the brains of both humans [5] [6] [7] and experimental animals [8] [9] [10] . In humans, HSV-1 is a common cause of sporadic viral encephalitis [11, 12] with mortality rates reaching 20-30% despite treatment [13] . Mice infected with HSV-1 can also develop lethal encephalitis with resistance to mortality being mouse strain dependent [14, 15] . Further, HSV-1 is implicated in the development of CNS demyelinating disease in humans but its' role remains controversial [16] [17] [18] [19] [20] . Although a high incidence of HSV-1 in the brains and active plaques of MS patients is reported [21, 22] , virus is also present in controls. Recent studies, however, report an increased risk of MS in HSV-1 infected individuals without the DRB1*15 allele [23] ; raising the possibility that this virus may play a role in the development of MS in individuals with a specific genotype. HSV-1 can also induce CNS demyelination in mice with the nature of the demyelinating lesions reported to be dependent on virus strain [24] [25] [26] [27] [28] [29] [30] [31] , route of infection [32] , and mouse strain [33, 34] . The mechanisms mediating the mouse strain effect are largely unknown. In this study, we combine histology, immunohistochemistry, and in-situ hybridization to investigate the relationship between virus and the development of lesions during the early stage (< 24 days PI) of demyelination in different strains of mice.
Methods

Mice
Inbred 8-10 week ♀ BL/6, BALB/c, SJL/J, A/J, and PL/J mice were purchased from the Jackson Laboratory, Bar Harbor, ME. Mice were housed in animal facilities of the Faculty of Medicine, University of British Columbia (UBC), and infected at 10 to 12 weeks of age. Principles of animal care (NIH publication No. 86-23, revised 1985) were followed in these studies along with the guidelines of the Institutional Animal Care and Use Committee of UBC.
Virus and cells
HSV-1 (strain 2) was grown on BHK-21 cells with viral titers determined by plaque assay [35] . This strain of HSV-1 was isolated from human trigeminal ganglia, plaque purified, and characterized by Dr. Moira Brown (MRC Institute for Virology, Glasgow) [35, 36] . The strain was selected from a large number of laboratory and clinical isolates because of the ability to induce CNS demyelination. Virus was stored at -80°C until used. The oral mucosa was inoculated with a sub-lethal dose, 2 × 10 5 plaque forming units (PFU) of virus, or mock infected using a scarification method previously described [33] .
Histology
The brains of three mice of each strain were removed at necropsy every 3 days PI and up to 30 days post-infection (PI). Additional mice were examined on intervening days as necessary.
Mice were perfused in-vivo with 4% paraformaldehyde in phosphate buffered saline (PBS). CNS tissue was dehydrated in alcohol and toluol, embedded in paraffin, and serially sectioned. Six micron thick coronal sections of the cerebral hemispheres (CR) along with transverse sections of the BST and cerebellum (CB) were made. Sections were counter stained with either hematoxylin-eosin (H & E), cresyl fast violet (CFV), or Luxol fast blue-cresyl fast violet (LFB-CFV). Sections were coded and examined in a blinded fashion with an Olympus BHS microscope.
Immunohistochemistry (IHC)
Serial sections of the CR and BST-CB were examined by PAP IHC. Detection of HSV viral antigens employed polyclonal rabbit anti-HSV-1 antisera (B0114) that recognizes all viral proteins (DAKO, Burlingham, ON). Sections were pretreated with 0.5% hydrogen peroxide and washed in 0.05 M Tris-saline (pH7.6) plus 1% normal goat serum prior to incubation with anti-sera. This was followed by treatment with goat anti-rabbit IgG, rabbit PAP, and 0.03% 3-3' diaminobenzydine. Sections were counterstained with either CFV or LFB-CFV.
In-situ hybridization (ISH)
Serial sections of the CR and BST-CB were examined by ISH. Sections were mounted on glass slides, deparaffinated, and rehydrated. Tissue was treated with 0.02 M HCL, washed, and treated with 0.01% Triton X-100 in PBS. Washed sections were treated with pronase (2.0 mg/ ml in 50 mM Tris-HCl, pH 7.4), postfixed in 4% paraformaldehyde in PBS, treated with 100 mM triethanlamine (pH 8.0) plus 25 mM acetic anhydride and dehydrated in ethanol. Sections were then treated with a prehybridization mixture (2x SSC, formamide, Denhardt's solution, salmon sperm DNA, dextran sulfate) for 20 min at room temperature (RT). This was followed by treatment with a hybridization mixture (2x SSC, dextran sulfate, formamide, salmon sperm DNA, DTT, Denhardt's solution, 35 Slabelled HSV cDNA) at 90°C for 7 min followed by 37°C for 16-24 hrs. The HSV cDNA probe was a 15 kb fragment (fragment G) derived from HSV-1 strain F and cloned in pTZ18. Specific activity of the probe was 2-7 × 10 8 cpm/μg of DNA. The fragment was previously determined not to cross react with cellular DNA. The tissue was washed, dehydrated in ethanol with 0.3 M ammonium acetate, air dried and coated with NTB-2 emulsion. The slides were stored at 4°C for two weeks, developed, and counterstained with H & E.
Statistics
All analyses for statistically significant differences were performed with Student's t test. P < 0.05 is considered significant.
Results
Three HSV-1 infected mice of each strain (BL/6, BALB/ c, SJL/J, A/J, and PL/J) were examined at necropsy every 3 days from day 0 through 30 PI. In some cases, additional mice were examined on intervening days along with mock infected controls. CR and BST-CB were serially sectioned and yielded~300 sections of the CR and 140 sections of the BST-CB per mouse. The serial sections were examined for viral DNA by ISH with H&E counterstain, for viral antigen by IHC and CFV counterstain, or both viral antigen and demyelination by IHC with LFB-CFV counterstain. None of the mock infected controls were positive for HSV-1 DNA, viral antigen, or CNS demyelination.
In BL/6 mice, HSV-1 DNA and antigen positive cells are restricted to the BST In BL/6 mice infected with HSV-1 strain 2 via the oral mucosa, the spread of infectious virus is restricted to the BST [37] and CNS demyelinating lesions do not occur [33] . To further examine the location of viral DNA and antigen in the brain, HSV-1 infected 10-12 week ♀ BL/6 mice were examined every 3 days from day 0 through 30 PI. Viral DNA and antigen positive cells cannot be identified throughout the brain nor are they present diffusely throughout the BST (data not shown). Viral DNA (Figure 1a In BALB/c mice, HSV-1 antigen positive cells appear sequentially in non-contiguous areas throughout the brain In BALB/c mice, infected with HSV-1 strain 2 via the oral mucosa, virus spreads throughout the brain [37] but CNS demyelinating lesions are restricted to the trigeminal root entry zone of the BST [33] . To identify viral antigen in the brain, HSV-1 infected 10-12 week ♀ BALB/c mice were examined every 3 days from day 0 through 30 PI. In contrast to BL/6 mice, viral antigen positive cells in BALB/c mice appear sequentially in non-contiguous areas throughout the brain. In SJL/J, A/J, and PL/J mice, 'focal' areas of viral antigen positive neuronal and non-neuronal cells appear sequentially in non-contiguous areas throughout the brain In SJL/J, A/J, and PL/J mice, infected with HSV-1 strain 2 via the oral mucosa, infectious virus spreads sequentially throughout the brain [33] and is associated with the development of early stage (< 24 days PI) CNS demyelination throughout the brain [34] . The number and size of the 'focal' areas of viral antigen positive cells were determined in every fourth section of the 140 serial BST-CB sections obtained from each of three mice of the three strains. To allow a comparison between the three mouse strains, IHC sections counterstained with CFV were examined on the first day the 'focal' areas appeared in the BST (day 9 PI in SJL/J mice and day 5 PI in A/J and PL/J mice) and the CB (day 12 PI in SJL/J mice, day 9 PI in A/J mice, and day 6 PI in PL/J mice) ( Table 2) . Differences in the 4 number and size of the 'focal' areas among the three strains were statistically significant ( Table 2) . Representative 'focal' areas in the BST of (a) SJL/J, 9 days PI (x400) (c) A/J, 6 days PI (x400) and (e) PL/J, 6 days PI (x400) mice are shown. Representative 'focal' areas in the CB of (b) SJL/J, 12 days PI (x200) (d) A/J, 9 days PI (x200) and (f) PL/J, 6 days PI (x200) mice are also shown. Sections of the CB were examined on the first day that 'focal' areas appear for each mouse strain. d Average number of 'focal' areas of viral antigen ± SD per section. Differences among mouse strains are all statistically significant at P < 0.001 except for the difference between SJL/J and A/J BST which was NS.
e As a single 'focal' area could be represented in several sections, the greatest diameter for each'focal' area was determined. The average diameter ± SD of the 'focal' areas for the three mouse strains was then calculated. Differences between the three mouse strains are all statistically significant at P < 0.001. Figure 5 'Focal' areas of HSV-1 antigen positive cells and demyelinating lesions co-localize throughout the brains of SJL/J, A/J, and PL/J mice. Serial IHC sections counterstained with LFB-CFV were examined for 'focal' areas of viral antigen positive cells and CNS demyelination in the BST and CB. 'Focal' areas and demyelinating lesions co-localize throughout the brains of 10-12 week ♀ SJL/J, A/J, and PL/J mice infected with HSV-1 via the oral mucosa. Initially, island of demyelination are identified within or adjacent to 'focal' areas of viral antigen. Representative sections from the CB of PL/J mice identify these areas within (white arrow) or adjacent to (black arrow) 'focal' areas of viral antigen (a) 8 days PI (x200) and (b) 9 days PI (x200). As the 'focal' areas of viral antigen are cleared, the demyelinating lesions increase in size. Representative sections from the CB of SJL/J mice identify areas of demyelination (arrows) adjacent to 'focal' areas of viral antigen (c) 14 days PI (x200) and (d) 15 days PI (x200). Although individual antigen positive cells can remain in the demyelinating lesions for a period of time (e) antigen positive cell (arrow) in the CB of PL/J mouse, 18 days PI (x200), 'focal' areas of viral antigen are eventually cleared (f) demyelinating lesions in the CB of PL/J mouse, 20 days PI (x200).
The relationship between 'focal' areas of HSV-1 antigen positive cells and demyelinating lesions was determined in every fourth section of the 140 serial BST-CB sections obtained from each of three mice of the three strains. To allow a comparison between the three mouse strains, IHC sections counterstained with LFB-CFV were examined on the first day demyelinating lesions appeared in the BST (day 12 PI in SJL/J mice and day 6 PI in A/J and PL/J mice) and the CB (day 15 PI in SJL/J mice, day 12 PI in A/J mice, and day 9 PI in PL/J mice) ( Table 3) . Although the number of 'focal' areas of antigen positive cells and demyelinating lesions is mouse strain dependent (Table 3) , in all mouse strains, the percentage of demyelinating lesions that co-localize with 'focal' areas of viral antigen is greater than 90%. Not all 'focal' areas of viral antigen co-localized with demyelinating lesions. [8] [9] [10] . The relationship between 35 S-labelled HSV-1 DNA positive cells and CNS demyelinating lesions was examined in adjacent serial sections of the BST-CB using histology and ISH. HSV-1 infected 10-12 week ♀ SJL/J, A/J, and PL/J mice were examined every 3 days from day 0 through 30 PI. Although infectious virus [34] and viral antigen (Table 1) are eventually cleared from the brains of all three mouse strains, the clearance of infectious virus precedes that of viral antigen. In contrast, HSV-1 DNA positive cells can remain in the brain beyond 25 days PI and are identified in demyelinating lesions of all three strains ( Figure 6 ). This is consistent with latently infected cells remaining in an area of demyelination.
Discussion
Mice infected with HSV-1 can develop CNS demyelinating lesions [24] [25] [26] [27] [28] [29] [30] [31] [32] but their development is determined by a number of factors including route of infection and virus strain. When infected in the pinna of the ear, BALB/cAJcl mice develop demyelination restricted to the descending root of the facial nerve [32] . When infected with the Rodanus strain of HSV-1, both Swiss and BALB/c mice develop demyelination restricted to the TREZ [24] [25] [26] [27] but when infected with Roziman strain F, demyelination develops in both the TREZ and BST of the two mouse strains [28] [29] [30] [31] . In contrast, BALB/c mice infected with a HSV-1 recombinant virus expressing IL-2 develop lesions in the optic nerve, brain, and spinal cord [38, 39] . Further, BALB/c mice infected with strains McKrae or KOS [38] [39] [40] or BL/6 mice infected with strain McRae [40] do not develop CNS demyelination but macrophage depleted BALB/c and BL/6 mice, infected with strain KOS or McKrae respectively, do develop lesions throughout the CNS [40] . A number of studies performed by Ghiasi and colleagues have implicated CD4 + CD25 + FoxP 3 + T cells as playing a pathogenic role in the development of demyelinating lesions when Il-12 p70 macrophages are ablated [40] .
Mouse strain can also influence the development of HSV-1 induced CNS demyelination. We previously reported that SJL/J, A/J, and PL/J but not BL/6 mice, infected with a sub-lethal dose of HSV-1 strain 2 via the oral mucosa, develop demyelinating lesions throughout the brain while lesions in BALB/c mice are restricted to the TREZ of the BST [33, 34] . The lesions are characterized by demyelination, a mononuclear cell infiltrate, and relative preservation of axons [33, 34, 41] . Further, SJL/J, Table 3 The relationship between 'focal' areas of HSV-1 antigen and demyelinating lesions in the BST-CB of inbred strains of mice b Both 'focal' areas of viral antigen and demyelinating lesions were determined in the BST of all three mouse strains. Sections of the BST were obtained on the first day demyelinating lesions appear in that mouse strain [24] .
c Both 'focal' areas of viral antigen and demyelinating lesions were determined in the CB of all three mouse strains. Sections of the CB were obtained on the first day demyelinating lesions appear in that mouse strain [24] . d Average number of 'focal' areas of viral antigen ± SD in the BST and CB of each of three mice. Differences among mouse strains are all statistically significant at P < 0.005. e Average number of demyelinating lesions ± SD among in the BST and CB of each of three mice. Differences among mouse strains are all statistically significant at P < 0.005.
A/J, and PL/J mice develop lesions sequentially throughout the brain during the early stage (< 24 days PI), but randomly in both A/J and PL/J mice during the intermediate stage (1-3 months PI), and only in PL/J mice during the late stage (> 3 months PI) of demyelination [34] . During the early stage of demyelination, lesions are immune mediated [42] , and their appearance correlates with the sequential spread of infectious virus throughout the brain [33, 37] . The number and size of the lesions follow a hierarchical order among the mouse strains [ 33, 34] . Although the influence of mouse strain on CNS infection is recognized and defined for a number of different viruses [43] [44] [45] [46] , our understanding of this effect on HSV-1 CNS infection, including the development of demyelination, is at a preliminary stage.
In this study we combine histology, IHC, and ISH to further define the effect of mouse strain on the development of early stage demyelination in mice infected with HSV-1 strain 2 via the oral mucosa.
Results of this study argue that HSV-1 induced CNS demyelination throughout the brain in susceptible strains of mice, develops in several stages. First, viral DNA and antigen positive cells appear sequentially throughout the brain, localize to non-contiguous areas of the brain, and primarily to cells with the morphology of neurons (Table 1) . This is consistent with previous reports on the spread and localization of HSV-1 in the brain [47] [48] [49] resulting from transneuronal transport of virus from the periphery to the CNS and synaptically determined relationships in the CNS [30, [49] [50] [51] [52] . However, results of this study indicate that this does not occur in all mouse strains. Although it is the case in BALB/c, SJL/J, A/J, and PL/J mice, it is not in BL/6 mice where viral DNA and antigen are restricted to a specific area of the BST. The restriction of HSV-1 to the BST in this strain was previously identified by viral titration studies [37] but the results of this study indicate a far greater degree of restriction occurs in the BST then was previously recognized.
Second, 'focal' areas of viral antigen positive neuronal and non-neuronal cells develop throughout the brain ( Table 1 ). The areas appear sequentially and localize to non-contiguous areas throughout the brain. Their development may result from the uptake and replication of HSV-1 in neurons resulting in the degeneration of infected cells, loss of cellular integrity, and release of virus [53] [54] [55] [56] . Having a high affinity for herpes viruses [57] [58] [59] , glia can become infected in areas surrounding the disintegrating neurons [28, 31] . Further, the development of 'focal' areas of viral antigen with HSV-1 has similarities to other herpes virus infections including pseudorabies virus where reactive gliosis and macrophage infiltration provides a barrier to the diffusion of virus through the extra-cellular compartment by isolating and phagocytosing virus [60, 61] . Results of our study identify (Table 2) . Previous studies have attributed differences in mouse strain susceptibility to the extent of glial infection with HSV-1 [33, 41, 62, 63] while other studies have reported differences in resistance to HSV-1to be mediated directly by glial cells [31, 64, 65] . A similar hierarchical order was previously identified for number and size of demyelinating lesions developing in the same strains of mice [34] .
Third, 'focal' areas of viral antigen positive cells co-localize with demyelinating lesions that develop throughout the brain (Table 3) . While the co-localization of 'focal' areas with demyelinating lesions occurs in SJL/J, A/J, and PL/J mice, they are restricted to a small area of the BST of BALB/c mice, and do not develop in BL/6 mice. Although the results argue that demyelinating lesions evolve from 'focal' areas of antigen positive cells, it is unclear if they develop from within or adjacent to the 'focal' areas.
Fourth, as 'focal' areas and individual viral antigen positive cells are cleared from the lesions, viral DNA positive cells, consistent with a latent infection, remain in the demyelinating lesions. Although viral latency in the CNS of mice is reported after infection with HSV-1 [8] [9] [10] , the presence of latent virus within demyelinating lesions of mice has not been previously reported to our knowledge.
Based on these results, we argue that the effect of mouse strain on the development of CNS demyelination during the early stage of HSV-1infection (< 24 days PI) is determined by the ability of virus to spread through the PNS and CNS of a specific mouse strain and the ability of the host to mount an immune response that restricts viral spread and clears virus from the brain. In all mouse strains infected with HSV-1 via the oral mucosa, virus spreads via retrograde axonal transport to the TG of the PNS [1, 2] and is followed by access to the CNS. In a number but not all mouse strains, virus spreads by transneuronal transport throughout the brain with the development of focal and non-contiguous neuronal infection determined by synaptically defined relationships in the CNS [30, [49] [50] [51] [52] . In many but not all mouse strains, this is followed by the development of 'focal' areas of antigen positive neuronal and nonneuronal cells that result from the replication of virus in neurons, degeneration of infected cells, release of virus [53] [54] [55] [56] , and subsequent infection of surrounding glia [57] [58] [59] . The hierarchical order of number and size of 'focal' areas reflects mouse strain differences in resistance of glia to HSV-1 [33, 41, 64, 65 ]. An immune response clears 'focal' areas of viral antigen positive cells from the CNS but results in the development of demyelinating lesions [42] . In A/J, PL/J, and SJL/J mice, viral antigen appears early throughout the brain but viral clearance is delayed until day 21 PI (Table 1) . A delay in the development of an immune response in these mouse strains could explain the delay in viral clearance and allow for the development of 'focal' areas of antigen positive neuronal and non-neuronal cells. In BL/6 mice, viral antigen also appears early in the CNS but in contrast to other mouse strains, virus is restricted to the BST. The restriction of viral spread and the failure to develop 'focal' areas of viral antigen positive cells is likely responsible for the absence of demyelinating lesions. Recently, we provided evidence that the restriction of viral spread in BL/6 mice results from redundancy in the immune system and mediated by NK/NKT and CD8 + T-lymphocytes [37] . Further, clearance of viral antigen from the brains of BL/6 mice occurs on day 12 PI; earlier then occurs in other mouse strains ( Table 1 ). The immune mechanisms mediating the clearance of virus has not yet been defined. In BALB/c mice, viral antigen also appears early throughout the brain (Table 1 ) but in this strain viral clearance occurs by day 18 PI. This is delayed compared to BL/6 mice but early when compared to SJL/J, A/J, and PL/J mice. The delay in clearance could explain the spread of virus throughout the brain but when compared to SJL/J, A/J, and PL/J mice, might be sufficient to clear virus before 'focal' areas of viral antigen positive cells develop.
Conclusions
When infected with a sub-lethal dose of HSV-1 lab strain 2 via the oral mucosa, susceptible SJL/J, A/J, and PL/J mice develop demyelinating lesions throughout the brain. In contrast, in moderately resistant BALB/c mice, demyelinating lesions are restricted to the TREZ of the BST. Resistant BL/6 mice do not develop CNS demyelination. In this study, we combine histology, IHC, and ISH to further investigate the effect of mouse strain on the early stage of demyelination (< 24 days PI).
Results of this study indicate that demyelinating lesions throughout the brain of susceptible mice develop in several stages. Initially, viral DNA and antigen infected cells, largely neurons, appear in non-contiguous areas throughout the brain. This is followed by the development of 'focal' areas of viral antigen positive neuronal and nonneuronal cells in non-contiguous areas throughout the brain. The number and size of the 'focal' areas follow a hierarchical order among the different mouse strains. Next, the 'focal' areas of viral antigen positive cells are seen to co-localize with demyelinating lesions suggesting they evolve from the 'focal' areas. As viral antigen positive cells and 'focal' areas are cleared, viral DNA positive cells consistent with a latent infection can remain in the areas of demyelination. All of these stages occur in susceptible SJL/J, A/J, and PL/J mice but not in moderately resistant BALB/c mice where 'focal' areas of antigen positive cells are restricted to a small area of the BST, and not in resistant BL/6 mice where 'focal' areas do not develop in the brain.
We hypothesize that the development of demyelinating lesions throughout the brain of susceptible mouse strains results from the non-contiguous spread of virus throughout the brain and the inability of the host to either restrict viral spread or clear virus from the brain prior to the development of 'focal' areas of viral antigen positive neuronal and non-neuronal cells.
